Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $98.1...